Insights from the IAPP Europe Data Protection Congress: Regulatory Convergence on AI and Sidley’s Women in Privacy Networking Lunch
The International Association of Privacy Professionals (IAPP) held its annual Europe Data Protection Congress in Brussels on November 15 & 16, 2023. Whilst the Congress covered a wide range of topics related to privacy, cybersecurity and the regulation of data more broadly, unsurprisingly a recurring theme throughout was the responsible development, commercialization and use of AI. In this regard panelists explored (amongst other things) what practical and effective AI governance may look like, the role of a Digital Ethics Officer, how to strike a balance between enabling innovation and safeguarding individual rights, and how AI may be used to automate data breach detection and response.
EU Moving Closer to an AI Act?
On 24 October 2023, the European Parliament and Member States concluded a fourth round of trilogue discussions on the draft Artificial Intelligence Regulation (AI Act). Policymakers agreed on provisions to classify high-risk AI systems and also developed general guidance for the use of “enhanced” foundation models. However, the negotiations did not lead to substantial progress on provisions for prohibitions in relation to the use of AI by law enforcement. The next round of trilogue discussions will take place on 6 December 2023.
AI Use in Drug Discovery
Artificial Intelligence (AI) has the potential to revolutionize how we find, develop, and deliver new life-saving therapies.
Join “State of the Art” host and Sidley partner Stephen Abreu as he speaks with Colin Hill, CEO and Co-Founder of Aitia. Together, they discuss the challenges and opportunities AI presents for the pharmaceutical industry, particularly how AI is accelerating the pace of drug discovery and its implications for the future of medicine.
Digital Health and Artificial Intelligence: New Developments From President Biden’s Executive Order
The Biden administration’s executive order issued on October 30, 2023, includes a number of initiatives relating to the development and use of artificial intelligence (AI), including in healthcare. As AI becomes a pivotal point of innovation for the healthcare industry, digital health healthcare technology developers, private equity sponsors, and other key industry stakeholders should track the regulatory frameworks certain to be developed following this executive order to better inform strategies for developing drugs and devices and assessing deals involving AI.
President Biden Signs Sweeping Artificial Intelligence Executive Order
On October 30, 2023, President Joe Biden issued an executive order (EO or the Order) on Safe, Secure, and Trustworthy Artificial Intelligence (AI) to advance a coordinated, federal governmentwide approach toward the safe and responsible development of AI. It sets forth a wide range of federal regulatory principles and priorities, directs myriad federal agencies to promulgate standards and technical guidelines, and invokes statutory authority — the Defense Production Act — that has historically been the primary source of presidential authorities to commandeer or regulate private industry to support the national defense. The Order reflects the Biden administration’s desire to make AI more secure and to cement U.S. leadership in global AI policy ahead of other attempts to regulate AI — most notably in the European Union and United Kingdom and to respond to growing competition in AI development from China.
New Export Controls on Advanced Computing and Semiconductor Manufacturing: Five Key Takeaways
On October 25, 2023, the U.S. Department of Commerce Bureau of Industry and Security (BIS) published updated export controls on advanced computing items and semiconductor manufacturing equipment under the Export Administration Regulations (EAR). Specifically, BIS published two interim final rules that revise and expand on the restrictions implemented in the initial interim final rule issued on October 7, 2022 (October 7, 2022 rule).1
AI Foundation Models: UK CMA’s Initial Report
The CMA has set out its emerging thinking on the functioning of competition and consumer protection in the market for foundation models.
Schumer Framework May Forge U.S. Model on AI Governance
*This article first appeared on Law360 on September 5, 2023.
This summer, Senate Majority Leader Chuck Schumer proposed a distinctive new framework to develop a comprehensive artificial intelligence regulatory policy that is intended to be adamantly bipartisan and committed, as a first principle, to preserving innovation and intellectual property rights.
Regulatory Update: National Association of Insurance Commissioners Summer 2023 National Meeting
The National Association of Insurance Commissioners (NAIC) held its Summer 2023 National Meeting (Summer Meeting) from August 12–16, 2023. Highlights include continued development of accounting principles and investment limitations related to certain types of bonds and structured securities, continued discussion of considerations related to private equity ownership of insurers, a proposed model bulletin addressing the use of artificial intelligence by the insurance industry, and continued development of a new consumer privacy protections model law.
EU, U.S., and UK Regulatory Developments on the Use of Artificial Intelligence in the Drug Lifecycle
Globally, the rapid advancement of artificial intelligence (AI) and machine learning (ML) raises fundamental questions about how the technology can be used. Drug approval authorities are now also taking part in this discussion, resulting in emerging and evolving guidelines and principles for drug companies.
